Univariate analysis of risk factors for occurrence of aGVHD
Characteristic . | Grades 0 to I aGVHD . | Grades II to IV aGVHD . | P . |
|---|---|---|---|
| No. patients | 41 | 34 | |
| Median recipient age, y (range) | 48 (33-63) | 51 (27-63) | .55 |
| Female donor, no. (%) | 19 (46) | 12 (35) | .33 |
| Negative CMV donor-recipient pair, no. (%) | 8 (19) | 3 (9) | .32 |
| Diagnosis, no. (%) | .12 | ||
| Myeloid malignancy | 20 (49) | 9 (26) | |
| Lymphoid malignancy | 11 (27) | 15 (44) | |
| Metastatic solid tumor | 10 (24) | 10 (29) | |
| Disease status, no. (%) | .04 | ||
| Standard risk* | 13 (32) | 4 (12) | |
| Advanced disease | 28 (68) | 30 (88) | |
| Conditioning regimen, no. (%) | .66 | ||
| ATG-based regimen | 27 (66) | 24 (71) | |
| Low-dose irradiation-based regimen | 14 (34) | 10 (29) | |
| GVHD prophylaxis, no. (%) | .82 | ||
| CSA alone | 24 (59) | 19 (56) | |
| CSA + mycophenolate mofetil | 17 (41) | 15 (44) | |
| Stem cell source, no. (%) | .56 | ||
| Bone marrow | 2 (5) | 0 | |
| Peripheral blood stem cells | 39 (95) | 34 (100) | |
| Median graft composition, (range, %) | |||
| CD34+, × 106/kg recipient body weight | 6.2 (2.0-12.9) | 5.5 (1.4-22.2) | .68 |
| CD3+, × 106/kg recipient body weight | 309 (14-689) | 328 (131-617) | .61 |
| Cytokine level, median (range) | |||
| IL-1β, pg/mL | 0 (0-17) | 0 (0-496) | .72 |
| IL-6, pg/mL | 0 (0-667) | 0 (0-33) | .66 |
| IL-8, pg/mL | 0 (0-336) | 0 (0-630) | .75 |
| IFN-α, pg/mL | 0 | 0 (0-817) | .65 |
| IFN-γ, pg/mL | 0 (0-478) | 0 (0-214) | .54 |
| IL-10, pg/mL | 0 (0-71) | 0 (0-36) | .21 |
| IL-12p70, pg/mL | 468 (0-4638) | 3606 (0-9000) | < .001 |
| IL-18, pg/mL | 0 (0-1495) | 0 (0-10453) | .21 |
| TNF-α, pg/mL | 0 (0-1) | 0 (0-200) | .84 |
| Fas-ligand, ng/mL | 0 (0-0.22) | 0 (0-0.64) | .53 |
Characteristic . | Grades 0 to I aGVHD . | Grades II to IV aGVHD . | P . |
|---|---|---|---|
| No. patients | 41 | 34 | |
| Median recipient age, y (range) | 48 (33-63) | 51 (27-63) | .55 |
| Female donor, no. (%) | 19 (46) | 12 (35) | .33 |
| Negative CMV donor-recipient pair, no. (%) | 8 (19) | 3 (9) | .32 |
| Diagnosis, no. (%) | .12 | ||
| Myeloid malignancy | 20 (49) | 9 (26) | |
| Lymphoid malignancy | 11 (27) | 15 (44) | |
| Metastatic solid tumor | 10 (24) | 10 (29) | |
| Disease status, no. (%) | .04 | ||
| Standard risk* | 13 (32) | 4 (12) | |
| Advanced disease | 28 (68) | 30 (88) | |
| Conditioning regimen, no. (%) | .66 | ||
| ATG-based regimen | 27 (66) | 24 (71) | |
| Low-dose irradiation-based regimen | 14 (34) | 10 (29) | |
| GVHD prophylaxis, no. (%) | .82 | ||
| CSA alone | 24 (59) | 19 (56) | |
| CSA + mycophenolate mofetil | 17 (41) | 15 (44) | |
| Stem cell source, no. (%) | .56 | ||
| Bone marrow | 2 (5) | 0 | |
| Peripheral blood stem cells | 39 (95) | 34 (100) | |
| Median graft composition, (range, %) | |||
| CD34+, × 106/kg recipient body weight | 6.2 (2.0-12.9) | 5.5 (1.4-22.2) | .68 |
| CD3+, × 106/kg recipient body weight | 309 (14-689) | 328 (131-617) | .61 |
| Cytokine level, median (range) | |||
| IL-1β, pg/mL | 0 (0-17) | 0 (0-496) | .72 |
| IL-6, pg/mL | 0 (0-667) | 0 (0-33) | .66 |
| IL-8, pg/mL | 0 (0-336) | 0 (0-630) | .75 |
| IFN-α, pg/mL | 0 | 0 (0-817) | .65 |
| IFN-γ, pg/mL | 0 (0-478) | 0 (0-214) | .54 |
| IL-10, pg/mL | 0 (0-71) | 0 (0-36) | .21 |
| IL-12p70, pg/mL | 468 (0-4638) | 3606 (0-9000) | < .001 |
| IL-18, pg/mL | 0 (0-1495) | 0 (0-10453) | .21 |
| TNF-α, pg/mL | 0 (0-1) | 0 (0-200) | .84 |
| Fas-ligand, ng/mL | 0 (0-0.22) | 0 (0-0.64) | .53 |
Variables with P < .10 in univariate analysis were included in the multivariate analysis.
CMV indicates cytomegalovirus.
Standard risk disease: chronic myeloid leukemia in chronic phase, acute leukemia in first complete remission